We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Skinbiotherapeutics Plc | LSE:SBTX | London | Ordinary Share | GB00BF33H870 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -1.13% | 8.75 | 8.50 | 9.00 | 8.85 | 8.75 | 8.85 | 309,158 | 13:20:51 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Biological Pds,ex Diagnstics | 132k | -2.84M | -0.0163 | -5.37 | 15.23M |
TIDMSBTX
RNS Number : 2209Y
SkinBioTherapeutics PLC
29 December 2023
SkinBioTherapeutics plc
("SkinBioTherapeutics" or the "Company")
Results of AGM
29 December 2023 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") announces that at the Company's Annual General Meeting, held today, all resolutions were duly passed.
Details of the proxy votes received on each resolution by the Company's Registrar are set out below:
Resolution For & Discretionary Against Withheld Number % Number % Number % of votes of votes of votes ------------------------- ------------- ------- ---------- ------ ---------- ------ Ordinary resolution to receive and adopt the directors' and auditors' report and the financial statements for year ended 01 30 June 2023 43,029,848 96.78% 1,413,649 3.18% 17,051 0.04% ------------------------- ------------- ------- ---------- ------ ---------- ------ Ordinary resolution for Gravita Audit Limited to be re-appointed as the auditors of the Company until the next 02 AGM 42,677,600 95.99% 448,075 1.01% 1,334,873 3.00% ------------------------- ------------- ------- ---------- ------ ---------- ------ Ordinary resolution for the Directors' to be authorised to fix the auditors' 03 remuneration 42,958,431 96.62% 186,707 0.42% 1,315,410 2.96% ------------------------- ------------- ------- ---------- ------ ---------- ------ Ordinary resolution for Stuart Ashman to be re-elected as a Director 04 of the Company 39,303,678 88.40% 2,636,183 5.93% 2,520,687 5.67% ------------------------- ------------- ------- ---------- ------ ---------- ------ Ordinary resolution for Martin Hunt to be re-elected as a Director 05 of the Company 39,991,885 89.95% 2,248,346 5.06% 2,220,317 4.99% ------------------------- ------------- ------- ---------- ------ ---------- ------ Ordinary resolution for Dr Catherine Prescott to be re-elected as a Director of 06 the Company 40,063,946 90.11% 3,072,834 6.91% 1,323,768 2.98% ------------------------- ------------- ------- ---------- ------ ---------- ------ Ordinary resolution for Danielle Bekker to be re-elected as a Director of 07 the Company 42,059,615 94.60% 972,653 2.19% 1,428,280 3.21% ------------------------- ------------- ------- ---------- ------ ---------- ------ Ordinary resolution for Manprit Singh Randhawa to be re-elected as a Director of 08 the Company 39,716,379 89.33% 2,419,340 5.44% 2,324,829 5.23% ------------------------- ------------- ------- ---------- ------ ---------- ------ Ordinary resolution to authorise the directors 09 to allot shares 42,030,813 94.54% 1,096,351 2.47% 1,333,384 3.00% ------------------------- ------------- ------- ---------- ------ ---------- ------ Special resolution to authorise the directors to disapply pre-emption 10 rights 42,285,656 95.11% 822,045 1.85% 1,352,847 3.04% ------------------------- ------------- ------- ---------- ------ ---------- ------ Special resolution to authorise the directors to disapply pre-emption rights in relation to an acquisition or other capital 11 investment 42,302,981 95.15% 804,720 1.81% 1,352,847 3.04% ------------------------- ------------- ------- ---------- ------ ---------- ------
-Ends-
For more information, please contact:
SkinBioTherapeutics plc Tel: +44 (0) 191 495 7325 Stuart J . Ashman, CEO Manprit Randhawa, CFO Cavendish Capital Markets Limited Tel: +44 (0) 20 7220 0500 (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson (Corporate Finance) Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales) Instinctif Partners (financial Tel: +44 (0) 20 7457 2020 press) SkinBioTherapeutics @instinctif.com Melanie Toyne-Sewell / Jack Kincade
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix(R) , is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps(TM), a food supplement to address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit : www.skinbiotherapeutics.com and www.axisbiotix.com.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
RAGNKCBQKBDDCBB
(END) Dow Jones Newswires
December 29, 2023 05:49 ET (10:49 GMT)
1 Year Skinbiotherapeutics Chart |
1 Month Skinbiotherapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions